Dieudonné Mumba Ngoyi

Prof. Dieudonné Mumba Ngoyi

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2009 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
PBPhilippe Büscher
Philippe Büscher
DNDieudonné Mumba Ngoyi
Dieudonné Mumba Ngoyi
JKJacques Kaboré
Jacques Kaboré
VLVeerle Lejon
Veerle Lejon
JRJo Robays
Jo Robays
SBSylvain Biéler
Sylvain Biéler

1 February 2019 in Brain Research Bulletin
Verified
Journal Article
Closed access
ALAnge Landela Luzolo
Ange Landela Luzolo
DNDieudonné Mumba Ngoyi
Dieudonné Mumba Ngoyi

7 January 2013 in Clinical and Translational Medicine
Verified
Journal Article
Open access
PDF file
NTNatalia Tiberti
Natalia Tiberti
EMEnock Matovu
Enock Matovu
AHAlexandre Hainard
Alexandre Hainard
JEJohn Charles Enyaru
John Charles Enyaru
VLVeerle Lejon
Veerle Lejon
Jean Charles SanchezJean Charles Sanchez
Jean Charles Sanchez
Accurate stage determination is crucial in the choice of treatment for patients suffering from sleeping sickness, also known as human African trypanosomiasis (HAT). Current staging methods, based on the counting of white blood cells (WBC) and the detection of parasites in the cerebrospinal fluid (CSF) have limited accuracy. We hypothesized that immune mediators reliable for staging T. b. gambiense HAT could also be used to stratify T. b. rhodesiense patients, the less common form of HAT.A population comprising 85 T. b. rhodesiense patients, 14 stage 1 (S1) and 71 stage 2 (S2) enrolled in Malawi and Uganda, was investigated. The CSF levels of IgM, MMP‐9, CXCL13, CXCL10, ICAM‐1, VCAM‐1, neopterin and B2MG were measured and their staging performances evaluated using receiver operating characteristic (ROC) analyses.IgM, MMP‐9 and CXCL13 were the most accurate markers for stage determination (partial AUC 88%, 86% and 85%, respectively). The combination in panels of three molecules comprising CXCL13‐CXCL10‐MMP‐9 or CXCL13‐CXCL10‐IgM significantly increased their staging ability to partial AUC 94% (p value < 0.01).The present study highlighted new potential markers for stage determination of T. b. rhodesiense patients. Further investigations are needed to better evaluate these molecules, alone or in panels, as alternatives to WBC to make reliable choice of treatment.

6 October 2021 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
PDF file
LMLeah F. Moriarty
Leah F. Moriarty
MNMandoko Papy Nkoli
Mandoko Papy Nkoli
JLJoris LOSIMBA LIKWELA
Joris LOSIMBA LIKWELA
PMPatrick Mulopo Mitashi
Patrick Mulopo Mitashi
ESEric Mukomena Sompwe
Eric Mukomena Sompwe
MGMESIA KAHUNU GAUTHIER
MESIA KAHUNU GAUTHIER
: Routine assessment of the efficacy of artemisinin-based combination therapies (ACTs) is critical for the early detection of antimalarial resistance. We evaluated the efficacy of ACTs recommended for treatment of uncomplicated malaria in five sites in Democratic Republic of the Congo (DRC): artemether-lumefantrine (AL), artesunate-amodiaquine (ASAQ), and dihydroartemisinin-piperaquine (DP). Children aged 6–59 months with confirmed Plasmodium falciparum malaria were treated with one of the three ACTs and monitored. The primary endpoints were uncorrected and polymerase chain reaction (PCR)-corrected 28-day (AL and ASAQ) or 42-day (DP) cumulative efficacy. Molecular markers of resistance were investigated. Across the sites, uncorrected efficacy estimates ranged from 63% to 88% for AL, 73% to 100% for ASAQ, and 56% to 91% for DP. PCR-corrected efficacy estimates ranged from 86% to 98% for AL, 91% to 100% for ASAQ, and 84% to 100% for DP. No pfk13 mutations previously found to be associated with ACT resistance were observed. Statistically significant associations were found between certain pfmdr1 and pfcrt genotypes and treatment outcome. There is evidence of efficacy below the 90% cutoff recommended by WHO to consider a change in first-line treatment recommendations of two ACTs in one site not far from a monitoring site in Angola that has shown similar reduced efficacy for AL. Confirmation of these findings in future therapeutic efficacy monitoring in DRC is warranted.

26 November 2023 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
MGMESIA KAHUNU GAUTHIER
MESIA KAHUNU GAUTHIER
STSarah Wellmann Thomsen
Sarah Wellmann Thomsen
LTLouise Wellmann Thomsen
Louise Wellmann Thomsen
Hypolite Muhindo MavokoHypolite Muhindo Mavoko
Hypolite Muhindo Mavoko
PMPatrick Mulopo Mitashi
Patrick Mulopo Mitashi
MAMichael Alifrangis
Michael Alifrangis
Partial artemisinin resistance, mediated by Plasmodium falciparum K13 (PfK13) mutations, has been confirmed in certain areas of East Africa that are historically associated with high-level antimalarial resistance. The Democratic Republic of Congo (DRC) borders these areas in the East. This study aimed to determine the prevalence of resistance markers in six National Malaria Control Program surveillance sites; Boende, Kabondo, Kapolowe, Kimpese, Mikalayi, and Rutshuru. The single nucleotide polymorphisms (SNPs) in P. falciparum genes PfK13, Pfdhfr, Pfdhps, Pfmdr1, and Pfcrt were assessed using targeted next-generation sequencing of isolates collected at enrollment in therapeutic efficacy studies. PfK13 SNPs were detected in two samples: in Kabondo (R561H) and in Rutshuru (P441L), both areas near Uganda and Rwanda. The Pfdhps ISGEGA haplotype, associated with reduced sulfadoxine-pyrimethamine chemoprevention efficacy, ranged from 0.8% in Mikalayi (central DRC) to 42.2% in Rutshuru (East DRC). R561H and P441L observed in eastern DRC are a concern, as they are associated with delayed artemisinin-based combination therapies-clearance and candidate marker of resistance, respectively. This is consistent with previous observations of shared drug resistance profiles in parasites of that region with bordering areas of Rwanda and Uganda. The likely circulation of parasites has important implications for the ongoing surveillance of partial artemisinin-resistant P. falciparum and for future efforts to mitigate its dispersal.

11 June 2020 in Microorganisms
Verified
Journal Article
Open access
PDF file
ETEvariste Tshibangu-Kabamba
Evariste Tshibangu-Kabamba
PNPatrick de Jésus Ngoma
Patrick de Jésus Ngoma
VTVo Phuoc Tuan
Vo Phuoc Tuan
TMTakashi Matsumoto
Takashi Matsumoto
JAJunko Akada
Junko Akada
Yoshio YamaokaYoshio Yamaoka
Yoshio Yamaoka
Antimicrobial susceptibility testing (AST) is increasingly needed to guide the Helicobacter pylori (H. pylori) treatment but remains laborious and unavailable in most African countries. To assess the clinical relevance of bacterial whole genome sequencing (WGS)-based methods for predicting drug susceptibility in African H. pylori, 102 strains isolated from the Democratic Republic of Congo were subjected to the phenotypic AST and next-generation sequencing (NGS). WGS was used to screen for the occurrence of genotypes encoding antimicrobial resistance (AMR). We noted the broad-spectrum AMR of H. pylori (rates from 23.5 to 90.0%). A WGS-based method validated for variant discovery in AMR-related genes (discovery rates of 100%) helped in identifying mutations of key genes statistically related to the phenotypic AMR. These included mutations often reported in Western and Asian populations and, interestingly, several putative AMR-related new genotypes in the pbp1A (e.g., T558S, F366L), gyrA (e.g., A92T, A129T), gyrB (e.g., R579C), and rdxA (e.g., R131_K166del) genes. WGS showed high performance for predicting AST phenotypes, especially for amoxicillin, clarithromycin, and levofloxacin (Youden’s index and Cohen’s Kappa > 0.80). Therefore, WGS is an accurate alternative to the phenotypic AST that provides substantial decision-making information for public health policy makers and clinicians in Africa, while providing insight into AMR mechanisms for researchers.